News, trade fairs, press information
LTS and LIVZON enter into license and collaboration agreement to develop and commercialize ASENAPINE TTS
LTS AG and Livzon Pharmaceutical Group Inc. announced today that the companies have entered into an exclusive license and collaboration agreement. LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).
New LTS Web seminar
LTS will host a web seminar titled ‘LTS Oral Thin Film Technology – Adaptable like a Chameleon’ .
LTS appoints Bas van Buijtenen as new Chief Executive Officer
LTS Lohmann Therapie-Systeme AG is very pleased to announce the appointment of Mr. Bas van Buijtenen to the role of Chief Executive Officer effective 1 June 2020.
LTS provides new insights
On 17.02. LTS has installed its first digital information display in Lohmannstraße, directly in front of the LTS gate.
Completion of solar panel installation at LTS Corp.
LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is pleased to announce the completion of the installation of solar panels atop of its warehouse building of its US affiliate, LTS Lohmann Therapy Systems, Corp.